

# Veklury<sup>®</sup> (remdesivir)

## Reconstitution When Sterile Water for Injection (SWFI) is Unavailable

Gilead Sciences, Inc. is providing this document to you, a US Healthcare Professional, in response to your unsolicited request for medical information. Some of the data may be outside of the US FDA-approved Prescribing Information. Gilead Sciences, Inc. does not intend to offer an opinion regarding the clinical relevance of these data or the advisability of administering any drug in a manner inconsistent with its approved labeling.

This document summarizes available information regarding Veklury<sup>®</sup> (remdesivir [RDV]) reconstitution when the preferred reconstitution diluent sterile water for injection (SWFI) is unavailable.

*The full indication, important safety information, and boxed warnings are available at: [https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury\\_pi.pdf](https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf)*

---

### Available Data

RDV for injection, 100 mg is recommended to be reconstituted with SWFI prior to further dilution into 0.9% sodium chloride for injection (NS).<sup>1</sup>

If the preferred reconstitution diluent SWFI is unavailable for reconstitution, NS may be used to reconstitute RDV.<sup>2</sup>

- **If NS is used to reconstitute RDV, then the subsequent dilution should only be done using 250 mL of NS.**<sup>2</sup>
- The dilution volume is recommended to be 250 mL because dilution of the 200 mg loading dose into 100 mL of NS results in osmolality greater than 400 mOsm/kg which may affect tolerability ([Table 1](#)).<sup>2</sup>

**Table 1. Osmolality of the Final Solution<sup>2</sup>**

Formulation	Reconstitution Diluent	Dilution Diluent	RDV Dose	Final Infusion Volume <sup>a,b</sup>	Osmolality
Veklury for Injection, 100mg (lyophilized powder)	SWFI	NS	100 mg	100 mL	317.5 mOsm/kg
				250 mL	299.0 mOsm/kg
			200mg	100 mL	351.7 mOsm/kg
				250 mL	314.2 mOsm/kg
	NS	NS	100 mg	100 mL	378.0 mOsm/kg
				250 mL	327.3 mOsm/kg
			200mg	100 mL	468.3 mOsm/kg
				250 mL	361.0 mOsm/kg

<sup>a</sup>The final diluted volume is per the recommended preparation instructions for adults.

<sup>b</sup>The proportionate amount of infusion fluid was removed from the IV bag prior to addition of dose volume to maintain the overall solution volume of 100 mL or 250 mL.

## References

1. VEKLURY, Gilead Sciences Inc. VEKLURY® (remdesivir) for injection, for intravenous use. VEKLURY® (remdesivir) injection, for intravenous use. U.S. Prescribing Information. Foster City, CA.
2. Gilead Sciences Inc. Data on File.

## Abbreviations

NS=0.9% normal saline  
RDV=remdesivir

SWFI=sterile water for injection

---

## Product label

For the full indication, important safety information, and Boxed Warning(s), please refer to the Veklury US Prescribing Information available at:

[https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury\\_pi.pdf](https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf)

## Follow up

For any additional questions, please contact Gilead Medical Information at:

☎ 1-866-MEDI-GSI (1-866-633-4474) or 🌐 <http://www.askgileadmedical.com/>

## Adverse event reporting

Please report all adverse events to:

Gilead Pharmacovigilance and Epidemiology ☎ 1-800-445-3235, option 3

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉ MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🌐 [www.accessdata.fda.gov/scripts/medwatch](http://www.accessdata.fda.gov/scripts/medwatch)

## Data privacy

The Medical Information service at Gilead Sciences may collect, store and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement ([www.gilead.com/privacy-statements](http://www.gilead.com/privacy-statements)) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact [privacy@gilead.com](mailto:privacy@gilead.com).

VEKLURY, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

© Gilead Sciences, Inc.